The article is devoted to the search for new solutions in the field of treatment of malignant ovarian tumors and, in particular, new approaches for overcoming immune resistance in a complex method of therapy. The experience of treating this pathology with an original method of postoperative immunotherapy using autologous immunomodulators, which, due to its simplicity and relatively low cost, should be widely used in gynecological oncology, is considered.